The Time Course Changes in Bone Metabolic Markers after Administering the Anti-Receptor Activator of Nuclear Factor-Kappa B Ligand Antibody and Drug Compliance among Patients with Osteoporosis

Kazuhide Inage¹, Sumihisa Orita¹, Kazuyo Yamauchi¹, Yoshihiro Sakuma², Go Kubota¹, Yasuhiro Oikawa³, Takeshi Sainoh¹, Jun Sato¹, Kazuki Fujimoto¹, Yasuhiro Shiga¹, Kazuhisa Takahashi¹, Seiji Ohtori¹

¹Department of Orthopedic Surgery, Graduate School of Medicine, Chiba University, Chiba, Japan
²Department of Orthopedic Surgery, National Hospital Organization Chiba Medical Center, Chiba, Japan
³Department of Orthopedic Surgery, Teikyo University Chiba Medical Center, Chiba, Japan

Asian Spine J 2015;9(3):338-343
http://dx.doi.org/10.4184/asj.2015.9.3.338

Corrections for Fig. 2, Fig. 3, and Fig. 4 in page 340 are needed.
There were some mistakes in the numerical values of the graphs. We apologize for any inconvenience that this may have caused.

Fig. 2. P1NP levels before and 1 month after administering the anti-RANKL antibody. P1NP, N-terminal propeptide of type 1 collagen; RANKL, receptor activator of nuclear factor-kappa B ligand; NS, not significant.
**Fig. 3.** The averages YAM level for the anti-RANKL antibody before and 6 months after treatment. YAM, young adult mean; RANKL, receptor activator of nuclear factor-kappa B ligand.

**Before correction**

![Graph showing YAM level before correction with p<0.05](image1)

**After correction**

![Graph showing YAM level after correction with p<0.05](image2)

**Fig. 4.** The time course changes by using the back pain VAS before treatment and 1, 2, 3, and 6 months after treatment. VAS, visual analogue scale; NS, not significant.

**Before correction**

![Graph showing back pain VAS before correction with p<0.01](image3)

**After correction**

![Graph showing back pain VAS after correction with p<0.01](image4)